A Brief History of Synthetic Biology
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Engineering a Circular Riboregulator in Escherichia Coli
bioRxiv preprint doi: https://doi.org/10.1101/008987; this version posted September 25, 2014. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Engineering a circular riboregulator in Escherichia coli William Rostain1,2, Shensi Shen2, Teresa Cordero1, Guillermo Rodrigo2,3 and Alfonso Jaramillo1,2,* 1 School of Life Sciences, University of Warwick, Coventry, CV4 7AL, United Kingdom. 2 Institute of Systems and Synthetic Biology, CNRS - Université d’Evry val d’Essonne, 91000 Évry, France. 3 Instituto de Biologia Molecular y Celular de Plantas, CSIC – Universidad Politécnica de Valencia, 46022 Valencia, Spain. * Corresponding author. School of Life Sciences, University of Warwick. Gibbet Hill Road, Coventry, CV4 7AL, United Kingdom. Tel: +44 (0)24 765 73432, E-mail: [email protected] Type: Letter Running title: Circular Riboregulator. Keywords: Biotechnology, Riboregulators, Splicing, Synthetic Biology. 1 bioRxiv preprint doi: https://doi.org/10.1101/008987; this version posted September 25, 2014. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract Circular RNAs have recently been shown to be important gene expression regulators in mammalian cells. However, their role in prokaryotes remains elusive. Here, we engineered a synthetic riboregulator that self-splice to produce a circular molecule, exploiting group I permuted intron-exon (PIE) sequences. We demonstrated that the resulting circular riboregulator can activate gene expression, showing increased dynamic range compared to the linear form. We characterized the system with a fluorescent reporter and with an antibiotic resistance marker. -
Improving Treatment of Genetic Diseases with Crispr-Cas9 Rna-Guided Genome Editing
Sanchez 3:00 Team R06 Disclaimer: This paper partially fulfills a writing requirement for first-year (freshmen) engineering students at the University of Pittsburgh Swanson School of Engineering. This paper is a student paper, not a professional paper. This paper is not intended for publication or public circulation. This paper is based on publicly available information, and while this paper might contain the names of actual companies, products, and people, it cannot and does not contain all relevant information/data or analyses related to companies, products, and people named. All conclusions drawn by the authors are the opinions of the authors, first- year (freshmen) students completing this paper to fulfill a university writing requirement. If this paper or the information therein is used for any purpose other than the authors' partial fulfillment of a writing requirement for first-year (freshmen) engineering students at the University of Pittsburgh Swanson School of Engineering, the users are doing so at their own--not at the students', at the Swanson School's, or at the University of Pittsburgh's--risk. IMPROVING TREATMENT OF GENETIC DISEASES WITH CRISPR-CAS9 RNA-GUIDED GENOME EDITING Arijit Dutta [email protected] , Benjamin Ahlmark [email protected], Nate Majer [email protected] Abstract—Genetic illnesses are among the most difficult to treat as it is challenging to safely and effectively alter DNA. INTRODUCTION: THE WHAT, WHY, AND DNA is the basic code for all hereditary traits, so any HOW OF CRISPR-CAS9 alteration to DNA risks fundamentally altering the way someone’s genes are expressed. This change could lead to What Is CRISPR-Cas9? unintended consequences for both the individual whose DNA was altered and any offspring they may have in the future, CRISPR-Cas9 is an acronym that stands for “Clustered compounding the risk. -
CRISPR/Cas9: Tools and Applications for Eukaryotic Genome Editing
CRISPR/Cas9: Tools and Applications for Eukaryotic Genome Editing Fei Ann Ran Broad Institute Cambridge, Massachusetts [email protected] I will provide some background on the CRISPR/Cas9 technology, some of the rationale for how we came to develop and use this tool, and I will address immediate questions concerning the specificity of the technology. I will also discuss some of the more interest- ing applications. Figure 1 reflects how the cost of DNA sequencing has decreased dramatically over the past two decades due to technological progress. As a result, there has been an explo- sion of data, not only in the sequences of different species, but in sequence differences between individuals within species, between cell types and between diseased and healthy cells. It suffices to say that this is an exciting time to be working in the field of genome engineering. Genome Engineering Typically, genome engineering is achieved by leveraging the cell’s own repair machinery. This can come from the error-prone NHEJ pathway that leads to insertion/deletion (in- del) mutations, which can be used to knock out genes, or, alternatively, we can supply a repair template to overwrite the site of a double-stranded break (DSB) for more-precise genome engineering via the HDR pathway (Figure 2). Figure 1. Advances in DNA-sequencing technologies. (Stratton MR et al., 2009) When we started working on CRISPR/Cas technology1, several well developed tools were already being used—and still are being used—to achieve impressive results in bio- technology, medicine, agriculture, and other fields. At the outset, we were interested in developing an alternative technology to make cloning easier at lower cost with greater scalability. -
Dynamic Signal Processing by Ribozyme-Mediated RNA Circuits to Control Gene Expression
bioRxiv preprint doi: https://doi.org/10.1101/016915; this version posted March 23, 2015. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Dynamic signal processing by ribozyme- mediated RNA circuits to control gene expression Shensi Shen1,†, Guillermo Rodrigo1,†, Satya Prakash3, Eszter Majer2, Thomas E. Landrain1, Boris Kirov1, José-Antonio Daròs2, and Alfonso 1,3,* Jaramillo 1 Institute of Systems and Synthetic Biology, Université d’Évry Val d’Essonne, CNRS, F-91000 Évry, France 2 Instituto de Biología Molecular y Celular de Plantas, CSIC - Universidad Politécnica de Valencia, 46022 Valencia, Spain 3 School of Life Sciences, University of Warwick, Coventry CV4 7AL, United Kingdom † Equal contribution to the work. * Correspondence: School of Life Sciences, University of Warwick, Coventry CV4 7AL, United Kingdom. E-mail: Alfonso.Jaramillo at warwick.ac.uk Manuscript information Type: Article. Subject category: RNA -- Synthetic Biology & Chemistry. Manuscript size: about 8,100 words (total). Abstract size: 144 words. Number of Figures: 6 (color). With Supplementary Information. 1" bioRxiv preprint doi: https://doi.org/10.1101/016915; this version posted March 23, 2015. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Abstract Organisms have different circuitries that allow converting signal molecule levels to changes in gene expression. -
Development and Applications of CRISPR-Cas9 for Genome Engineering
Leading Edge Review Development and Applications of CRISPR-Cas9 for Genome Engineering Patrick D. Hsu,1,2,3 Eric S. Lander,1 and Feng Zhang1,2,* 1Broad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, MA 02141, USA 2McGovern Institute for Brain Research, Department of Brain and Cognitive Sciences, Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA 3Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA 02138, USA *Correspondence: [email protected] http://dx.doi.org/10.1016/j.cell.2014.05.010 Recent advances in genome engineering technologies based on the CRISPR-associated RNA- guided endonuclease Cas9 are enabling the systematic interrogation of mammalian genome function. Analogous to the search function in modern word processors, Cas9 can be guided to specific locations within complex genomes by a short RNA search string. Using this system, DNA sequences within the endogenous genome and their functional outputs are now easily edited or modulated in virtually any organism of choice. Cas9-mediated genetic perturbation is simple and scalable, empowering researchers to elucidate the functional organization of the genome at the systems level and establish causal linkages between genetic variations and biological phenotypes. In this Review, we describe the development and applications of Cas9 for a variety of research or translational applications while highlighting challenges as well as future directions. Derived from a remarkable microbial defense system, Cas9 is driving innovative applications from basic biology to biotechnology and medicine. Introduction of the genome and its functions. In biotechnology, precise The development of recombinant DNA technology in the 1970s manipulation of genetic building blocks and regulatory machin- marked the beginning of a new era for biology. -
Signal Integration: Applications of RNA Riboregulator Capabilities Kyliah Clarkson, Natasha Tuskovich, Derek Jacoby, Chris Tuttle, Layne Woodfin
Signal Integration: Applications of RNA Riboregulator Capabilities Kyliah Clarkson, Natasha Tuskovich, Derek Jacoby, Chris Tuttle, Layne Woodfin Department of Biochemistry and Microbiology, University of Victoria, Victoria, BC Introduction Background – Biothermometer Background - Ribolock and Ribokey Self-complementary messenger RNA has a high potential for tunable repression An RNA hairpin will also unfold when exposed to a sequence of higher of translation. A self-complementary hairpin which includes the Shine-Dalgarno site An RNA hairpin will unfold when exposed to temperatures past the melting point for the sequence. This permits the temperature-sensitive expression of the specificity. When the expression of such a complementary sequence is controlled by in the stem will greatly reduce protein expression until the necessary conditions are a separate promoter, this permits a condition-sensitive expression of the downstream met for the hairpin to completely unfold. downstream gene. The TUDelft 2008 iGEM team retrieved natural RNA thermometers from three species, then sequenced and redesigned them to test for a gene. The condition may be the presence or absence of a metabolite, of an antibiotic modified temperature range. We worked with their 32°C thermometer as it was or toxin, or of various wavelengths of light. The Berkeley 2006 iGEM team began found to be their most effective. with the ribosome binding site hairpin (the "ribolock") and the highly specific complementary sequence (the "ribokey") produced by Collins et al., then redesigned the lock and key sequences to reduce background transcription and increase activated transcription. Figure 1. Temperature sensitive hairpin loop Figure 2. The 32°C temperature sensitive hairpin part of TUDelft Figure 3. -
Recombinant S. Pyogenes CRISPR-Cas9 Catalog Number: 9957-C9
Recombinant S. pyogenes CRISPR-Cas9 Catalog Number: 9957-C9 DESCRIPTION Source E. coli-derived s. pyogenes CRISPR-Cas9 protein S. pyogenes CRISPR-Cas9 KRPAATKKAGQAKK- APKKKRKVGIHGVPAA (Asp2-Asp1368) HHHHHH KKGYGRKKRRQRRRG Accession # Q99ZW2 N-terminus C-terminus N-terminal Sequence Ala Analysis Predicted Molecular 164 kDa Mass SPECIFICATIONS SDS-PAGE 133 kDa, reducing conditions Activity Measured by its ability to cleave a targeted DNA substrate. S. pyogenes CRISPR-Cas9 achieves >80% substrate cleavage, as measured under the described conditions. Endotoxin Level <0.10 EU per 1 μg of the protein by the LAL method. Purity >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining. Formulation Supplied as a 0.2 μm filtered solution in Tris, NaCl, EDTA, Glycerol and TCEP. See Certificate of Analysis for details. Activity Assay Protocol Materials Assay Buffer: 50 mM NaCl, 10 mM Tris-HCl, 10 mM MgCl2, 100 µg/mL BSA, pH 7.9 Recombinant Streptococcus pyogenes CRISPR-Cas9 (rS. pyogenes Cas9) (Catalog # 9957-C9) PBR322 vector (NEB, Catalog # N3033S) digested with EcoRI-HF (NEB, Catalog # R3101S)* Dharmacon synthetic sgRNA, targeting sequence: GAGGCAGACAAGGTATAGGG Ethidium Bromide, 10 mg/mL (Amresco, Catalog # X328) Ultrapure DNase/RNase-Free Distilled Water (Invitrogen, Catalog # 10977015), to prepare Assay Buffer DNA gel *Digest was gel purified using gel purification kit and eluted in EB buffer (10 mM Tris-HCl, pH 8.5). Assay 1. Prepare RNP Complex: a. 600 nM sgRNA (6 µL addition from 3 µM stock prepared in Assay Buffer) b. 0.25 μg rS. pyogenes Cas9 c. Add Assay Buffer for a final RNP Complex volume of 26.5 µL d. -
(12) Patent Application Publication (10) Pub. No.: US 2007/0136827 A1 Collins Et Al
US 2007013 6827A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2007/0136827 A1 Collins et al. (43) Pub. Date: Jun. 14, 2007 (54) CSFTRANS RIBOREGULATORS Publication Classification (51) Int. Cl. (75) Inventors: James J. Collins, Newton, MA (US); AOIK 67/027 (2006.01) Farren J. Isaacs, Brookline, MA (US); C7H 2L/04 (2006.01) Charles R. Cantor, Del Mar, CA (US); CI2N 15/09 (2006.01) Daniel J. Dwyer, Brookline, MA (US) CI2N 5/06 (2006.01) (52) U.S. Cl. ............................ 800/14; 435/325; 435/455; 536/23.2 Correspondence Address: CHOATE, HALL & STEWART LLP (57) ABSTRACT TWO INTERNATIONAL PLACE BOSTON, MA 02110 (US) The present invention provides nucleic acid molecules, DNA constructs, plasmids, and methods for post-transcrip tional regulation of gene expression using RNA molecules to (73) Assignee: TRUSTEES OF BOSTON UNIVER both repress and activate translation of an open reading SITY, Boston, MA (US) frame. Repression of gene expression is achieved through the presence of a regulatory nucleic acid element (the cis-repressive RNA or crRNA) within the 5' untranslated (21) Appl. No.: 10/535,128 region (5' UTR) of an mRNA molecule. The nucleic acid element forms a hairpin (stem/loop) structure through complementary base pairing. The hairpin blocks access to (22) PCT Fed: Nov. 14, 2003 the mRNA transcript by the ribosome, thereby preventing translation. In particular, in embodiments of the invention PCT No.: PCT/USO3A36506 designed to operate in prokaryotic cells, the stem of the (86) hairpin secondary structure sequesters the ribosome binding S 371(c)(1), site (RBS). -
CRISPR/Cas9 System and Gene Editing Tools – on Patent Rights, Recent Disputes and Its Potential Commercial Applicability in Biotechnology and Medicine
ISSN 2003-2382 CRISPR/Cas9 system and gene editing tools – On patent rights, recent disputes and its potential commercial applicability in biotechnology and medicine By Thomas Hedner and Jean Lycke ABSTRACT may also find a future use in “de-extinction” of various animals such as the woolly mammoth The CRISPR/Cas9 discovery has emerged as a and passenger pigeon. powerful technology tool to edit genomes, which The recent discoveries and developments have allows researchers, innovators and life science led to extensive patenting efforts, resulting in some entrepreneurs to alter DNA sequences and modify major patent disputes. The extensive patenting may gene function in a range of species. The simplicity, risk creating a scenario, which could hamper the high efficiency and seemingly broad use of the further development of this technology and ultima- CRISPR/Cas9 system has led to hopes that this tely limit full value creation of this technology for disruptive technology may have the potential to major societal and industrial stakeholders. transform important sectors of biotechnology and medicine. The technology will enable users to make changes in the sequence or expression of virtually 1. INTRODUCTION any gene, cell type or organism. The rapid progress The CRISPR technology, which allows researchers to easily in the development of CRISPR/Cas9-based techno- alter DNA sequences and modify gene function has over logies over the past years has been extraordinary. the past decade emerged a simple and powerful tool for In spite of that, many outstanding questions remain editing genomes1 The CRISPR/Cas9 is a system initially to be addressed, and potentially interesting applica- found in bacteria as a mechanism involved in immune tions as well as potential risks yet need to be explored. -
CRISPR/Cas9 Genome Editing Brochure
mirusbio.com Cas9 Target Sequence Guide RNA GENOME EDITING: CRISPR/CAS9 DELIVERY METHODS GENOME EDITING: CRISPR/CAS9 DELIVERY What is CRISPR/Cas9 Genome Editing? The CRISPR/Cas9 system is a powerful tool for genome editing in mammalian cells that allows researchers to generate genetic variants at lower cost and with higher throughput than alternative methods like zinc finger nuclease (ZFN) or transcription activator-like effector nuclease (TALEN) genome editing. Cas9 PAM Genomic DNA Target Sequence Guide RNA crRNA tracrRNA The CRISPR/Cas9 RNP Complex. The CRISPR associated protein 9 (Cas9) endonuclease (blue) is targeted to DNA by a guide RNA (gRNA), which can be supplied as a two-part system consisting of CRISPR RNA (crRNA) and trans-activating crRNA (tracrRNA) or as a single guide RNA (sgRNA), where the crRNA and tracrRNA are connected by a linker (dotted line). Target recognition is facilitated by the protospacer-adjacent motif (PAM). A double strand break (DSB) occurs 3 bp upstream of the PAM. CRISPR Facilitates Multiple Types of Genome Modification Cleavage of Target DNA By Cas9 Deletion Modication Insertion Multiple Genomic Alterations are Possible Following Cleavage of Target DNA by Cas9. Variable length insertions and/ or deletions (indels) can result near the DNA break due to mistakes in DNA repair by the endogenous non-homologous end joining (NHEJ) pathway. These indels frequently result in disruption of gene function. Alternatively, by supplying a DNA repair template, researchers can leverage the homology-directed repair (HDR) pathway to create defined deletions, insertions or other modifications. 2 TO ORDER | Toll Free 888.530.0801 | Direct 608.441.2852 | www.mirusbio.com Glossary of CRISPR Terms Term Definition CRISPR Associated Protein 9 - Cas9 is an RNA-guided DNA endonuclease from the type Cas9 II CRISPR system of Streptococcus pyogenes that has been adapted for use in genome editing applications. -
Engineering of Primary Human B Cells with CRISPR/Cas9 Targeted Nuclease Received: 26 January 2018 Matthew J
www.nature.com/scientificreports OPEN Engineering of Primary Human B cells with CRISPR/Cas9 Targeted Nuclease Received: 26 January 2018 Matthew J. Johnson1,2,3, Kanut Laoharawee1,2,3, Walker S. Lahr1,2,3, Beau R. Webber1,2,3 & Accepted: 23 July 2018 Branden S. Moriarity1,2,3 Published: xx xx xxxx B cells ofer unique opportunities for gene therapy because of their ability to secrete large amounts of protein in the form of antibody and persist for the life of the organism as plasma cells. Here, we report optimized CRISPR/Cas9 based genome engineering of primary human B cells. Our procedure involves enrichment of CD19+ B cells from PBMCs followed by activation, expansion, and electroporation of CRISPR/Cas9 reagents. We are able expand total B cells in culture 10-fold and outgrow the IgD+ IgM+ CD27− naïve subset from 35% to over 80% of the culture. B cells are receptive to nucleic acid delivery via electroporation 3 days after stimulation, peaking at Day 7 post stimulation. We tested chemically modifed sgRNAs and Alt-R gRNAs targeting CD19 with Cas9 mRNA or Cas9 protein. Using this system, we achieved genetic and protein knockout of CD19 at rates over 70%. Finally, we tested sgRNAs targeting the AAVS1 safe harbor site using Cas9 protein in combination with AAV6 to deliver donor template encoding a splice acceptor-EGFP cassette, which yielded site-specifc integration frequencies up to 25%. The development of methods for genetically engineered B cells opens the door to a myriad of applications in basic research, antibody production, and cellular therapeutics. -
User Method: Alt-R CRISPR-Cas9 RNP Complexes for Microinjection Into B
user method genome editing Microinjection of Bactrocera tryoni (Queensland fruit fly) embryos How to prepare Alt-R® CRISPR-Cas9 ribonucleoprotein complexes for microinjection Contributed by Amanda Choo, University of Adelaide, Adelaide, South Australia The method presented here is provided by customers who have used the Alt-R CRISPR-Cas9 System. This can serve as a starting point for using the Alt-R CRISPR-Cas9 System in similar biological systems, but may not be fully optimized for your gene or application. IDT does not guarantee these methods, and application specialists at IDT can only provide general guidance with limited troubleshooting and support. Materials Kits and reagents Ordering information Enzyme dilution reagents: Option 1: HEPES and KCl General laboratory supplier Option 2: 1X Phosphate buffered saline (PBS) General laboratory supplier Option 3: Opti-MEM® media Thermo Fisher (cat # 51985091) IDT predesigned and custom crRNA: Alt-R CRISPR-Cas9 crRNA www.idtdna.com/CRISPR-Cas9 Alt-R CRISPR-Cas9 tracrRNA IDT (cat # 1072532, 1072533, 1072534) or Alt-R CRISPR-Cas9 tracrRNA – ATTO™ 550 IDT (cat # 1075927, 1075928) Alt-R S.p. Cas9 Nuclease 3NLS IDT (cat # 1074181, 1074182) Nuclease-Free Duplex Buffer IDT (cat # 11-01-03-01) Reagents for 10X Injection buffer: Sodium phosphate General laboratory supplier KCl General laboratory supplier Nuclease-Free Water IDT (cat # 11-05-01-14) HDR template: Ultramer® DNA Oligonucleotides IDT (www.idtdna.com/Ultramer) See what more we can do for you at www.idtdna.com. user method genome editing Methods A. Prepare buffers and enzyme 1. Prepare the Cas9 enzyme working buffer as described in the following table: Component Amount Final concentration 1 M HEPES, pH 7.5 200 µL 20 mM 1 M KCl 1.5 mL 150 mM Nuclease-Free Water ~6.5 mL* — Final volume 10 mL — * Add 6.5 mL of water, verify pH 7.5, and add more water to reach final volume.